The company's share price jumped 31% by mid-afternoon.
BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today announced success in the Phase I/II clinical trial to test the safety of its universal flu vaccine. The test included six participants, who received a double dosage of the vaccine, the highest approved dosage for the trial. The company will now expand the double dosage trial to 24 participants on the basis of the approved trial protocol.
BiondVax's universal flu vaccine is aimed at creating a season and multi-strain protection against most human influenza virus strains. The vaccine has not been tested against specific flu strains, nor has it been found to be effective against swine flu.
BiondVax has obtained the permission of the safety committee to proceed with the clinical trial of its second-generation universal flu vaccine at the Sourasky Medical Center Tel Aviv (Ichilov Hospital).
BiondVax's share rose 31% by mid-afternoon to NIS 7.46.
Published by Globes [online], Israel business news - www.globes-online.com - on August 3, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009